Macroview Investment Management LLC bought a new stake in iShares Biotechnology ETF (NASDAQ:IBB – Get Rating) during the 4th quarter, HoldingsChannel reports. The firm bought 198 shares of the financial services provider’s stock, valued at approximately $26,000.
Several other hedge funds and other institutional investors have also bought and sold shares of IBB. Vontobel Holding Ltd. lifted its holdings in iShares Biotechnology ETF by 9.5% in the first quarter. Vontobel Holding Ltd. now owns 5,060 shares of the financial services provider’s stock valued at $659,000 after buying an additional 440 shares during the period. Blair William & Co. IL lifted its holdings in iShares Biotechnology ETF by 9.7% in the first quarter. Blair William & Co. IL now owns 18,717 shares of the financial services provider’s stock valued at $2,439,000 after buying an additional 1,659 shares during the period. NewEdge Advisors LLC lifted its holdings in iShares Biotechnology ETF by 11.7% in the first quarter. NewEdge Advisors LLC now owns 13,777 shares of the financial services provider’s stock valued at $1,796,000 after buying an additional 1,445 shares during the period. DCF Advisers LLC acquired a new position in iShares Biotechnology ETF in the first quarter valued at $912,000. Finally, Laurel Wealth Advisors Inc. lifted its holdings in iShares Biotechnology ETF by 22.6% in the first quarter. Laurel Wealth Advisors Inc. now owns 3,019 shares of the financial services provider’s stock valued at $393,000 after buying an additional 557 shares during the period. Institutional investors and hedge funds own 58.02% of the company’s stock.
iShares Biotechnology ETF Stock Performance
IBB stock opened at $124.50 on Friday. The company’s fifty day simple moving average is $131.94 and its 200 day simple moving average is $128.98. iShares Biotechnology ETF has a 12-month low of $104.29 and a 12-month high of $138.74.
About iShares Biotechnology ETF
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
- Get a free copy of the StockNews.com research report on iShares Biotechnology ETF (IBB)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Biotechnology ETF (NASDAQ:IBB – Get Rating).
Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.